Navigation Links
Resverlogix Board of Directors Update
Date:11/26/2008

M) PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
2. Resverlogix Announces Closing of Debt Redemption
3. Resverlogix Eliminates Sixty Percent of Remaining Debt
4. Resverlogix Issues a Management Statement
5. Resverlogix Board of Directors Update
6. Resverlogix Notice of Conference Call & Webcast
7. Jan Gray Joins Resverlogix Board of Directors
8. Resverlogixs Lead Drug Featured in Key Scientific Publication
9. Industry Leaders Select Resverlogixs RVX-208
10. /C O R R E C T I O N from Source -- Resverlogix Corp./
11. Resverlogix Notice of Conference Call & Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... York , September 23, 2014 ... leading provider of  Closed System Transfer     Devices ... exclusive partnership with Taiwanese distributor MedFront Medical Technology Corporation.  Equashield,s ... in Taiwan , ... as the company continues to expand globally, and ...
(Date:9/23/2014)... 23, 2014 Dr. Williams says, “Find ... on healthcare offers a three phase process that can ... delivery system that would go far beyond anything previously ... the delivery of healthcare.” , “Every effort to improve ... to provide discernable progress throughout that system because all ...
(Date:9/23/2014)... England , September 23, 2014 ... launched with funding from Imperial Innovations, Cambridge Innovation Capital ... Inivata, a clinical cancer genomics company focused on ... analysis to improve cancer testing and treatment, today ... round led by Imperial Innovations and including Cambridge ...
(Date:9/22/2014)... and SANTA CLARA, Calif. , Sept. ... WBMD ), the leading source of health information, ... survey that provide novel insights regarding physician and ... and care.  Dr. Eric Topol , a leading ... who serves as both Editor-in-Chief of Medscape and Chief ...
Breaking Biology Technology:Equashield Enters Taiwan Following Expansion to Australia, Japan, China 2Dr. Ira Williams Offers the Healthcare Solution Necessary for Patient Safety Improvement 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 2WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 3WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 4
... Scheduled for Thursday, May 15th at 5 PM ... ... IMRX ) today announced that the Company has postponed its live,webcast and ... quarter 2008 financial results; this call was originally,scheduled for Tuesday, May 13, 2008, ...
... Interleukin Genetics,Inc. (Amex: ILI ) announced today that ... Rodman and Renshaw 5th Annual Global,Healthcare Conference on Monday ... The conference will be held at Le Meridien Beach ... of the presentation will be available on the,Investors section ...
... BETHLEHEM, Pa., May 13 Particle Sciences has expanded,its ... ft Class 1000 (ISO 6),clean room. The space also ... was added to the existing 15,000 sq ft facility ... manufacturing,especially that of semisolids, suspensions and dispersions. "This,investment is ...
Cached Biology Technology:Interleukin Genetics to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference 2
(Date:9/23/2014)... 2014 Research and Markets  has announced ... and Opportunities, 2019" report to their offering. ... enhancing security and protection in private as well as ... country,s government is focusing on using biometric systems to ... national IDs that are of crucial importance to the ...
(Date:9/23/2014)... CORAL SPRINGS, Florida , September 23, 2014 ... listings for innovative companies in tech sector position for significant ... generation products & services.  Companies in focus today are: NXT-ID, ... (NYSE: BABA ), Mobileye N.V. (NYSE: ... ReWalk Robotics Ltd. (NASDAQ: RWLK) NXT-ID, Inc. (NASDAQ: ...
(Date:9/23/2014)... have parasitic DNA fragments called "jumping genes" that insert ... process. And that phenomenon can result in age-related diseases ... Rochester now report that the "jumping genes" in mice ... protein stops keeping them in check in order to ... published today in Nature Communications , Professor of ...
Breaking Biology News(10 mins):India Biometrics Market Forecast and Opportunities, 2019 2India Biometrics Market Forecast and Opportunities, 2019 3Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 2Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 3Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 4Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 5Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 6Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 7A multi-function protein is key to stopping genomic parasites from 'jumping' 2
... the 20th EORTCNCIAACR Symposium on "Molecular Targets and ... from Tuesday 21 October-Friday 24 October. Today ... accommodation via the official local agent if you ... the European Organisation for the Research and Treatment ...
... national trial of a catheter-based treatment for deep ... in combination with clot removal devices to prevent ... of a blood clot in a leg vein). ... permanent damage to the veins, resulting in debilitating ...
... Wayne State University have tested a breast cancer vaccine ... even cancers resistant to current anti-HER2 therapy - without ... 15 issue of Cancer Research, a journal ... vaccine could treat women with HER2-positive, treatment-resistant cancer or ...
Cached Biology News:Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics 2Pivotal national trial uses newest interventional radiology treatment to bust blood clots in legs 2Pivotal national trial uses newest interventional radiology treatment to bust blood clots in legs 3Vaccine against HER2-positive breast cancer offers complete protection in lab 2Vaccine against HER2-positive breast cancer offers complete protection in lab 3
... BacMagic™ DNA Kit provides a positive selection ... recombinant protein expression in insect cells. The ... generating recombinant baculoviruses by eliminating the time-consuming ... is an AcNPV genome with a portion ...
... CLS number is a new product number, ... If showing no availability yet, please order ... contact customer service for assistance. ... Dim: surface area 500 cm 2 ...
Mouse Anti-Human Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 (KIR2DL4 Monoclonal Antibody Family: New...
Gridded Cell Culture Petri Dish (20 mm molded in base), tissue-culture treated...
Biology Products: